Global Wellness Strategies

Global Wellness Strategies

Global Wellness Strategies operates at the intersection of asset management and biotech incubation, translating a broad wellness mandate into targeted investments in psychedelic medicine and mental health infrastructure. The firm's most visible vehicle is Xtacy Therapeutics, a publicly oriented life sciences platform that structures clinical-stage bets. Through Xtacy, the firm holds positions in Core One Labs, a Vancouver-based biotech that produces biosynthetic psilocybin and operates a network of clinics in the Netherlands, signaling a pipeline that runs from molecule to patient delivery. The investment strategy spans early-stage venture, late-stage growth, and expansion capital, with a sector focus concentrated on regulated psychedelics, neurotherapeutics, and integrated wellness delivery models. Known portfolio concentration includes Core One Labs, a company advancing recombinant psychedelic active pharmaceutical ingredients (APIs) and clinical therapies for mental health disorders. The firm engages through direct equity positions and platform-building structures, rather than fund-of-funds or club-deal models, and maintains a geographic focus on North American drug development with select European clinical delivery assets. Team size and total deployment remain undisclosed, and the firm has not publicly reported custodial or consulting mandates outside the Xtacy Therapeutics umbrella. No additional offices or philanthropic foundations have been identified. The most recent operational signal is the ongoing integration of Core One Labs' biosynthesis capabilities and clinic partnerships under the Xtacy platform, though no dated fund close or leadership change has been announced in the last 24 months that can be independently confirmed. What distinguishes Global Wellness Strategies structurally is its hybrid posture: it is neither a pure-play life sciences venture fund nor a passive holding entity. The firm operates through a proprietary corporate platform — Xtacy Therapeutics — which both houses investments and appears to provide strategic operating oversight, a model more common in natural resources or real estate than in mental health therapeutics. This architecture concentrates governance and deployment authority within a single corporate structure, a departure from the limited partnership model used by most Canadian biotech investors.